

ERRATUM

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes

Fernando Gomez-Peralta · Cristina Abreu · Albert Lecube ·
Diego Bellido · Alfonso Soto · Cristóbal Morales · Miguel Brito-Sanfiel ·
Guillermo Umpierrez

Published online: August 23, 2017
© The Author(s) 2017. This article is an open access publication

Erratum to: Diabetes Ther
DOI 10.1007/s13300-017-0277-0

In the original publication, corresponding author e-mail address and Fig. 2 were published incorrectly. The correct e-mail address and the revised Fig. 2 are given here.

The corresponding author's e-mail address should read as fgomezp@saludcastillayleon.es.

The incorrect statement in Fig. 2 “BP <140/80 mmHg, aged older than 65 years or hemodynamically unstable*?” should read as “BP <140/80 mmHg, aged older than 65 years or hemodynamically unstable**?”

The online version of the original article can be found under doi:[10.1007/s13300-017-0277-0](https://doi.org/10.1007/s13300-017-0277-0).

F. Gomez-Peralta (✉) · C. Abreu
Endocrinology and Nutrition Unit, Segovia General Hospital, Segovia, Spain
e-mail: fgomezp@saludcastillayleon.es

A. Lecube
Endocrinology and Nutrition Unit, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida, CIBERDEM (CIBER de Diabetes y Enfermedades Metabólicas Asociadas, ISCIII), University of Lleida, Lleida, Spain

D. Bellido
Endocrinology and Nutrition Section, Hospital Marcide, Ferrol, Spain

A. Soto
Endocrinology and Nutrition Department, Hospital de La Coruña, A Coruña, Spain

The incorrect statement in Fig. 2 “Reintroduce treatment according to clinical situation**?” should read as “Reintroduce treatment according to clinical situation***?”

C. Morales
Endocrinology and Nutrition Department, Virgen Macarena Hospital, Seville, Spain

M. Brito-Sanfiel
Endocrinology and Nutrition Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

G. Umpierrez
Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA




Fig. 2 Proposed algorithm for adjusting antidiabetic agents (a) and diuretic/antihypertensive therapy (b) when initiating SGLT2 inhibitors in patients with type 2 diabetes. *DPP4i* DPP4 inhibitors, *GI* gastrointestinal, *GLP1ra* GLP-1 receptor agonists, *SU* sulfonylureas, *SMBG* self-monitoring of blood glucose, *BP* blood

pressure. *Avoid insulin withdrawal to minimize the risk of euglycemic diabetic ketoacidosis. **Hemodynamically unstable defined as atrial fibrillation, orthostatic hypotension or blood pressure lability, prior syncope, etc. ***Clinical situation defined by congestive heart failure, edema, renal function

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial

use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.